OPKO Health (NASDAQ:OPK) Issues Earnings Results

OPKO Health (NASDAQ:OPK) released its quarterly earnings data on Thursday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09, Zacks reports. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%.

OPKO Health Stock Down 1.8 %

OPKO Health stock traded down $0.03 during trading hours on Thursday, hitting $1.63. The company had a trading volume of 4,816,978 shares, compared to its average volume of 2,823,192. The firm has a market capitalization of $1.11 billion, a P/E ratio of -8.58 and a beta of 1.63. The firm’s fifty day moving average is $1.54 and its 200-day moving average is $1.55. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a fifty-two week low of $0.86 and a fifty-two week high of $1.76.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 500,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was purchased at an average price of $1.56 per share, for a total transaction of $780,000.00. Following the transaction, the chief executive officer now owns 212,411,477 shares in the company, valued at $331,361,904.12. This trade represents a 0.24 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders acquired 1,521,609 shares of company stock valued at $2,313,710. Insiders own 47.26% of the company’s stock.

Analysts Set New Price Targets

OPK has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Wednesday, January 8th. Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th. Finally, StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.